Loading clinical trials...
Loading clinical trials...
A Double-blind, Double-dummy, Randomised, Placebo-controlled, 4-way, Crossover, Multi-centre Phase II Study With Budesonide as an Active Control to Evaluate the Efficacy and Safety of 2 Doses of Inhaled AZD5423 Over 7 Days in Patients With Mild Allergic Asthma Challenged With an Inhaled Allergen
Conditions
Interventions
AZD5423
Budesonide 200 microgram
+2 more
Locations
4
Canada
Research Site
Calgary, Alberta, Canada
Research Site
Hamilton, Ontario, Canada
Research Site
Québec, Quebec, Canada
Research Site
Saskatoon, Saskatchewan, Canada
Start Date
November 1, 2010
Primary Completion Date
December 1, 2011
Completion Date
December 1, 2011
Last Updated
April 2, 2015
NCT07486401
NCT07219173
NCT02327897
NCT04706988
NCT04639791
NCT06471257
Lead Sponsor
AstraZeneca
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions